Brainvectis - Crunchbase Company Profile & Funding

Q: When was the last funding round for Brainvectis?

Brainvectis closed its last funding round on obfuscated from a Series A round.

Q: How much funding has Brainvectis raised to date?

Brainvectis has raised obfuscated.

Overview

Brainvectis

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Brainvectis

CB Rank

212379

Treat neurodegenerative diseases by restoring brain cholesterol metabolism

Acquired by

Asklepios BioPharmaceutical

Founded

obfuscation

Private

Series A

Fontenay-aux-roses, Ile-de-France, France

1-10

www.brainvectis.com/

Medical

Medical Device

Therapeutics

Funding Rounds

Series A

OBF

obfuscation

Key People

Nathalie Cartier Lacave: FOUNDER

Details

Legal Name

Brainvectis SAS

Operating Status

Active

Company Type

For Profit

Founders

Christian Allouche, Nathalie Cartier Lacave

About the Company

Brainvectis is focused on the development of treatments that focus on neurodegenerative diseases such as Huntington’s and Alzheimer’s diseases. It researches about the restoration of brain cholesterol metabolism by increasing CYP46A1 in the patients’ brains.

Brainvectis was founded by Nathalie Cartier Lacave in 2015. It is based in

Fontenay-aux-Roses, France.

Predictions & Insights

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Growth Insight

Products & Services

AB-1005

A gene therapy aimed at treating Parkinson’s disease by delivering the GDNF gene directly to the brain to restore dopamine levels.

ACT-101

A gene therapy for Late-Onset Pompe Disease (LOPD) designed to deliver a functioning copy of the GAA gene to the liver to potentially eliminate the need for enzyme replacement therapy.

Research & Development

Brainvectis is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Brainvectis	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Brainvectis	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Brainvectis	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Brainvectis	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Brainvectis	—	obfuscated obfuscation	—	Series A

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Brainvectis	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Brainvectis	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Brainvectis	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Brainvectis	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Brainvectis	—	obfuscated obfuscation	—	Series A